Galectin Therapeutics Inc (US: GALT) — Healthcare · Share Price, Chart & Market Data
About: Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.48 (+6.43%)
GALTGalectin Therapeutics Inc
Loading watchlist status…
Trade GALT now
Galectin Therapeutics Inc share price
GALT price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 4:24 pm GMT+0
GALT price performance
8.768%
5D
-7.466%
1M
-38.768%
YTD
87.871%
1Y
GALT price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
US rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 4:24 pm GMT+0
GALT details
GALT Market Signals